
Palatin reports $5.1 million loss as obesity drug trials advance
Key points
- Palatin Technologies recorded a $5.06 million net loss in fiscal first-quarter 2027, while revenue fell to $361,802 from $8.85 million.
- Cash declined to $3.74 million from $7.49 million at June 30, 2026, and the company warned that additional funding is needed to continue operations.
- Obesity drug development continues, with the first human study of its long-acting MC4R peptide targeted for the first half of 2027.
Palatin Technologies (NASDAQ:PTN) reported a fiscal first-quarter 2027 net loss of $5.06 million, compared with net income of $4.68 million in the same period of fiscal 2026.
Collaboration and license revenue fell 95.9% to $361,802 from $8.85 million, as the previous-year period included upfront and milestone payments under licensing arrangements.
Current-quarter revenue consisted of reimbursements for research and development services performed under the company's agreement with Boehringer Ingelheim, while research and development expenses increased to $3.38 million from $2.53 million.
Cash and cash equivalents declined to $3.74 million at September 30, 2026, from $7.49 million at June 30, 2026, while operating activities used $3.74 million during the quarter.
Management stated that additional financing is required and substantial doubt exists about the company's ability to continue operating for one year following the financial statements' issuance.
Palatin focuses on developing melanocortin receptor medicines, particularly MC4R agonists targeting rare obesity-related conditions such as hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndrome.
The company has selected PL2001, a long-acting MC4R peptide candidate, for clinical development and targets its first human study for the first half of 2027, with initial data expected in the second half.
Its oral small-molecule programme targets a first human study in the second half of 2027 and initial data in the first half of 2028, subject to ongoing development activities.

